Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540783 | 1.00 | DGAT1 (0.40) | DGAT1IDO1GCKWNT3ALMNA | |
| SCHEMBL13009528 | 0.91 | DGAT1 (0.40) | DGAT1IDO1WNT3ALMNAALDH1A1 | |
| SCHEMBL14199021 | 0.91 | DGAT1 (0.40) | DGAT1IDO1WNT3ALMNAALDH1A1 | |
| SCHEMBL13009517 | 0.89 | KDM4E (0.38) | DGAT1IDO1WNT3ALMNAALDH1A1 | |
| SCHEMBL3543032 | 0.82 | IDO1 (0.50) | DGAT1IDO1 | |
| SCHEMBL3543034 | 0.82 | IDO1 (0.50) | DGAT1IDO1 | |
| SCHEMBL16660897 | 0.80 | DRD4 (0.43) | DGAT1IDO1 | |
| SCHEMBL16969426 | 0.80 | DGAT1 (0.47) | DGAT1IDO1WNT3ALMNAALDH1A1 | |
| SCHEMBL3537299 | 0.80 | DGAT1 (0.49) | DGAT1ALDH1A1KDM4ERAB9A | |
| SCHEMBL16053525 | 0.79 | DGAT1 (0.42) | DGAT1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885IDO1 2690/4885GCK 99/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885IDO1 2567/4885GCK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.